

Circulating Nucleosomes for Detection of Colorectal Cancer and High-risk Advanced Adenomas

Li-Chun CHANG¹, Marielle HERZOG², Nathalie HARDAT², Dorian PAMART², Han-Mo CHIU¹

¹Department of Internal Medicine, National Taiwan University Hospital, Taipei 10002, Taiwan.

²Belgian Volition SRL, 22 Rue Phocas Lejeune, Parc Scientifique Crealys, 5032 Isnes, Belgium









Background and aim

- Approximately 60% of Fecal immunochemical tests (FITs) are false-positive and result in a lot of unnecessary colonoscopies.
- There is an unmet need for a simple test to supplement FIT to triage individuals at higher risk who require colonoscopy referrals.
- FIT is less effective in detecting proximal lesions even advanced neoplasms.
- We investigated the levels of circulating free nucleosomes containing different epigenetic modifications in patients referred for colonoscopy and the detection rate of proximal neoplasms.



Material and Methods

- 520 average-risk asymptomatic patients: (i) CRC (n= 33), (ii) advanced adenoma (AA) (n=123, including 18 with AA>2cm); (iii) non-AA (n=168); (iv) non-neoplastic polyps (n=30); (vi) colonoscopy negative control (n=166).
- Plasma and stool samples were obtained prior to colonoscopy.
- Circulating Nucleosome levels:
 - ✓ Nu.Q® quantitative immuno-assays: Belgian Volition SRL, Belgium.
 - ✓ 7 different assays measuring: H3.1-, H3K27Me3-, H3K36Me3-, H3K9Me3-, H3K14Ac-, H3K27Ac- and H3R8Cit-nucleosomes.
- FIT: OC-SENSOR (Eiken Chemical Co., Ltd., Tokyo, Japan) using positive cut-off of 20ug/g feces.



Results

Nu.Q® biomarkers (H3K27Me3 and H3R8Cit) plus FIT improved sensitivity for CRC and AA

Combination of two Nu.Q® biomarkers H3K27Me3 and H3R8Cit with FIT allowed:

• The detection of all CRC and 94.3% of AA, including all the high-risk adenomas.

• The detection of 50/55 proximal adenomas including 3 proximal AA >2cm not detected

by FIT.


8	

Diagnosis	Positive Triage Test		
Diagnosis	FIT	Nu.Q® + FIT	
CRC	33/33	33/33	
Advanced Adenoma (AA)	112/123	116/123	
<= 1cm	45/48	43/48	
1-2 cm	52/57	55/57	
> 2 cm (high risk AA)	15/18	18/18	
Non-AA	141/168	149/167	
Non-neoplastic polyps	28/30	25/30	
Control	137/166	131/165	

Results

Nu.Q® biomarkers: H3K27Me3 and H3R8Cit plus FIT could reduce unnecessary colonoscopies

 The same combination could reduce unnecessary colonoscopies by 21.8% and 23.3% in control and non-neoplastic polyps subgroups respectively.



Conclusion

- H3K27Me3 and H3R8Cit-nucleosome levels in combination with FIT in a logistic regression model could:
 - ✓ Improve the detection of proximal high-risk AA
 - ✓ Provide a non-invasive method to reduce unnecessary colonoscopy
- Combination use of a nucleosome blood test with FIT may improve the effectiveness and could reduce the overall cost of FIT-based screening.